SocialPicks Monitor new  |    Stock Idea Community
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 King Pharmaceuticals Inc.  (KG) Trade Now »     Rate KG  -  Discuss KG  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate KG:



KG Analysis & Videos »


KG: Bull or Bear?

Full Calendar on Tap for FDA through Year-End Graphic_rating_buy KG
Rxlogo
76%
 -15.56%
in 8 days

Full Calendar on Tap for FDA through Year-End



The accompanying table presents an updated calendar of 30 decision dates which either have deadlines before year-end or represent delays in previously expected decisions in which the FDA has not issued a new date for a final decision.

After the close today, Pain Therapeutics (PTIE) and King Pharma (KG) announced mixed results from a FDA panel review of Remoxy, which is designed to be an abuse-resistant opiate pain drug in response to abuse and diversion issues with drugs such as Purdue Pharma's OxyCont
...
By  Mike Havrilla   (-6.40%  risk: moderate)  11/13/08 Comment


More Pain to Come from the FDA? Graphic_rating_buy KG
Rxlogo
76%
 +10.80%
in 22 days
(closed on 11/13/08)

More Pain to Come from the FDA?


The accompanying table (click on image to enlarge) presents an updated calendar of expected FDA decision dates. Surprisingly, the FDA issued a complete response letter to Abbott Labs (ABT) for Vicodin CR, an extended-release version of the widely used painkiller that the company expected to be approved this quarter. Three more companies face key FDA decision in the month of December for abuse-resistant forms of opiate pain drug candidates. King Pharma (KG) and Pain Therapeutics (PTIE) await a decision on Remoxy while Alpharma (ALO)
...
By  Mike Havrilla   (-6.40%  risk: moderate)  10/22/08 Comment


FDA Decision Date Calendar for 2009 Graphic_rating_buy KG
Rxlogo
76%
 -11.59%
in 28 days
(closed on 10/22/08)

FDA Decision Date Calendar for 2009


The accompanying table presents a calendar of expected FDA regulatory approval decisions for 2009, including a March 1st deadline to expand the label of cancer drug Erbitux in what has now become a hostile takeover attempt by Bristol-Myers (BMY) for the remaining 83% stake in ImClone Systems (IMCL) it does not already own. Two other companies which are highly leveraged to their upcoming FDA decision include Pain Therapeutics (PTIE) and King Pharma (KG) for Remoxy, which are due to hear back from the agency this yea
...
By  Mike Havrilla   (-6.40%  risk: moderate)  09/24/08 Comment


Get free stock alert for KG:
Your Email Address:


King Pharmaceuticals Inc. Graphic_rating_buy KG
Foto
69%
 -29.09%
in 123 days
King Pharmaceuticals, Inc. provides branded prescription pharmaceutical products worldwide. It primarily offers branded prescription products for primary care physicians, neurologists, orthopedic surgeons, hospitals, internal medicine physicians, allergists, pediatricians, and pain specialists. These products include neuroscience products, such as Skelaxin, Avinza, and Sonata; hospital products, such as Thrombin-JMI and Synercid; acute care products that comprise Bicillin and Intal; and legacy products consisting of Altace, Levoxyl, and Cytomel. The company also develops, manufactures, and ...
By  Marian Filo   (-36.63%  risk: aggressive)  07/21/08 Comment


King Pharmaceuticals a buy - market has overreacted in selloff Graphic_rating_buy KG
 4 %
 -51.92%
in 480 days
Down about 20% in a few months. market has overreacted to the possibility that Altace patent might be invalidated early which is set to expire in April 2009.

Cash flow has grown about 25% per year for the past seven years. Altace currently makes up 32% of sales.

Assuming no further growth the current cash flow discounted to present value valued KG at almost double the current price. Subtracting 100% of the altace sales makes KG still undervalued by greater than 30%. A great bargain for a company with a good history of increasing cash flow. Seems likely to grow at least 50% in ...
By  colindelia   (-59.62%  risk: conservative)  07/30/07 Comment





People Bullish on KG

Rxlogo
Mike Havrilla
Principal
76%
7 days ago

fernandes
Sr. Analyst
32%
14 days ago

sperri100
Analyst
81%
2 mos ago

buyandhold
Principal
69%
3 mos ago

ono333
Analyst
55%
3 mos ago


People Bearish on KG

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 29.65 +61.65% 160
2 Gerald Greene 21.24 +48.89% 50
3 The Big Bear 19.00 +49.44% 205
4 krprasad 17.77 +19.60% 4
5 David Young 15.63 +16.16% 6


POPULAR STOCKS
Symbol Company Name Sentiment
BA The Boeing Company
WM Washington Mutual Inc
AMZN Amazoncom Inc
BIDU Baiducom Inc ADS
IBM International Business Machines Corp
AMD Advanced Micro Devices Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 


StreetInsider.com on KG


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About King Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch